Solaris Endovascular Exceeds Enrollment Milestone for DEScover Trial; Interim Data to be Shared at Vascular Conferences
Solaris Endovascular, Inc., a growth-stage U.S.-based medical device company specializing in advanced endovascular solutions, today announced that 80% of patients have now been enrolled in the pivotal DEScover randomized clinical trial.